Agenus Inc Stock Performance
| AGEN Stock | USD 3.09 0.07 2.22% |
The firm shows a Beta (market volatility) of 1.9, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Agenus will likely underperform. At this point, Agenus Inc has a negative expected return of -0.0303%. Please make sure to confirm Agenus' potential upside, rate of daily change, and the relationship between the sortino ratio and skewness , to decide if Agenus Inc performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Agenus Inc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy technical and fundamental indicators, Agenus is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return (2.22) | Five Day Return (11.97) | Ten Year Return (96.93) | All Time Return (99.96) |
Last Split Factor 1:20 | Last Split Date 2024-04-12 |
1 | Agenus Secures 22 Million Mortgage and Announces Strategic Operational Realignment | 11/27/2024 |
2 | Acquisition by Garo Armen of 5347 shares of Agenus at 3.05 subject to Rule 16b-3 | 12/13/2024 |
3 | Acquisition by Garo Armen of 5931 shares of Agenus at 2.75 subject to Rule 16b-3 | 12/27/2024 |
4 | Acquisition by Hirsch Susan B of 6416 shares of Agenus subject to Rule 16b-3 | 12/31/2024 |
5 | Acquisition by Wright Timothy of 2532 shares of Agenus subject to Rule 16b-3 | 01/02/2025 |
6 | Acquisition by Garo Armen of 1040 shares of Agenus at 15.69 subject to Rule 16b-3 | 01/06/2025 |
7 | Acquisition by Garo Armen of 4777 shares of Agenus at 3.12 subject to Rule 16b-3 | 01/10/2025 |
8 | SaponiQx, Probius, and Ginkgo Bioworks Unite to Revolutionize Vaccine Adjuvant Development | 01/21/2025 |
9 | Agenus Presents Data at ASCO GI Demonstrating Impact of BOTBAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease | 01/22/2025 |
10 | Acquisition by Garo Armen of 4169 shares of Agenus at 3.57 subject to Rule 16b-3 | 01/24/2025 |
11 | Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in RelapsedRefractory Metastatic Sarcomas | 01/29/2025 |
12 | Agenus Is Attractively Priced Despite Fast-paced Momentum | 02/06/2025 |
13 | Acquisition by Garo Armen of 4251 shares of Agenus at 3.5 subject to Rule 16b-3 | 02/07/2025 |
14 | Agenus BOTBAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting | 02/12/2025 |
15 | Disposition of 37500 shares by Jennifer Buell of Agenus at 11.8 subject to Rule 16b-3 | 02/14/2025 |
16 | CORRECTING and REPLACING Agenus BOTBAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting | 02/24/2025 |
17 | Agenus to Participate in B. Riley Securities Precision Oncology Radiopharma Investor Conference | 02/25/2025 |
| Begin Period Cash Flow | 181.3 M |
Agenus |
Agenus Relative Risk vs. Return Landscape
If you would invest 342.00 in Agenus Inc on November 28, 2024 and sell it today you would lose (33.00) from holding Agenus Inc or give up 9.65% of portfolio value over 90 days. Agenus Inc is currently does not generate positive expected returns and assumes 5.4839% risk (volatility on return distribution) over the 90 days horizon. In different words, 48% of stocks are less volatile than Agenus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Agenus Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Agenus' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Agenus Inc, and traders can use it to determine the average amount a Agenus' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0055
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AGEN |
Estimated Market Risk
| 5.48 actual daily | 48 52% of assets are more volatile |
Expected Return
| -0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Agenus is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Agenus by adding Agenus to a well-diversified portfolio.
Agenus Fundamentals Growth
Agenus Stock prices reflect investors' perceptions of the future prospects and financial health of Agenus, and Agenus fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Agenus Stock performance.
| Return On Equity | -12.79 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (1.42) % | ||||
| Operating Margin | (1.33) % | ||||
| Current Valuation | 108.1 M | ||||
| Shares Outstanding | 23.61 M | ||||
| Price To Earning | 10.52 X | ||||
| Price To Book | 218.61 X | ||||
| Price To Sales | 0.45 X | ||||
| Revenue | 156.31 M | ||||
| Gross Profit | (28.68 M) | ||||
| EBITDA | (145.92 M) | ||||
| Net Income | (245.76 M) | ||||
| Cash And Equivalents | 218.23 M | ||||
| Cash Per Share | 0.72 X | ||||
| Total Debt | 350.25 M | ||||
| Debt To Equity | 5.88 % | ||||
| Current Ratio | 1.45 X | ||||
| Book Value Per Share | (13.48) X | ||||
| Cash Flow From Operations | (224.2 M) | ||||
| Earnings Per Share | (11.02) X | ||||
| Market Capitalization | 72.96 M | ||||
| Total Asset | 313.91 M | ||||
| Retained Earnings | (1.96 B) | ||||
| Working Capital | (143.48 M) | ||||
| Current Asset | 63.4 M | ||||
| Current Liabilities | 9.97 M | ||||
About Agenus Performance
By examining Agenus' fundamental ratios, stakeholders can obtain critical insights into Agenus' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Agenus is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 29.43 | 27.96 | |
| Return On Tangible Assets | (0.99) | (1.04) | |
| Return On Capital Employed | (3.16) | (3.00) | |
| Return On Assets | (0.90) | (0.95) | |
| Return On Equity | 1.38 | 1.45 |
Things to note about Agenus Inc performance evaluation
Checking the ongoing alerts about Agenus for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Agenus Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Agenus Inc generated a negative expected return over the last 90 days | |
| Agenus Inc has high historical volatility and very poor performance | |
| Agenus Inc has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 156.31 M. Net Loss for the year was (245.76 M) with loss before overhead, payroll, taxes, and interest of (28.68 M). | |
| Agenus Inc currently holds about 218.23 M in cash with (224.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.72. | |
| Agenus Inc has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Agenus to Participate in B. Riley Securities Precision Oncology Radiopharma Investor Conference |
- Analyzing Agenus' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Agenus' stock is overvalued or undervalued compared to its peers.
- Examining Agenus' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Agenus' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Agenus' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Agenus' stock. These opinions can provide insight into Agenus' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agenus Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agenus. If investors know Agenus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agenus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.02) | Revenue Per Share | Quarterly Revenue Growth 0.033 | Return On Assets | Return On Equity |
The market value of Agenus Inc is measured differently than its book value, which is the value of Agenus that is recorded on the company's balance sheet. Investors also form their own opinion of Agenus' value that differs from its market value or its book value, called intrinsic value, which is Agenus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agenus' market value can be influenced by many factors that don't directly affect Agenus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agenus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Agenus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agenus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.